IgniteData has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) and AstraZeneca to launch its innovative Archer tool for Electronic Health Record (EHR)-to-Electronic Data ...

The Lancet research papers build on the WHO’s Guidance for best practices in clinical trials released in September 2024.

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –– Enrolling approximately one patient per week ...

On October 22, 2024, we acquired privately-held Opus Genetics Inc., a clinical-stage gene therapy company focused on IRDs, in ...

Keros plans on engaging with regulatory authorities, starting in the third quarter of 2025. Subject to the outcome of these regulatory interactions, Keros expects to initiate a Phase 2 clinical trial ...

The first clinical trial of a generative AI therapy bot suggests it was as effective as human therapy for people with ...

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...

European clinicians and scientists are to receive £5.5m in funding to form a world-leading research team tasked with making ...

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.

The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...